OrthoPediatrics Corp

OrthoPediatrics Corp(KIDS)股票分析

$22.030

+0.079 (+0.36%)收盘时

Loading chart…
最高
22.280
开盘
21.900
成交量加权均价
22.07
成交量
209.14K
市值
686.03M
最低
21.900
成交额
4.62M
企业价值/息税折旧摊销前利润(TTM)
128.04

OrthoPediatrics Corp. is an orthopedic company, which is focused on advancing the field of pediatric orthopedics. The Company is engaged in designing, developing, and marketing anatomically appropriate implants and devices for children with orthopedic conditions, giving pediatric orthopedic surgeons and caregivers. The Company sells its specialized products, including PediLoc, PediPlates, Cannulated Screws, PediFlex nail, PediNail, PediLoc Tibia, ACL Reconstruction System, Locking Cannulated Blade, Locking Proximal Femur, Spica Tables, RESPONSE Spine, BandLoc, Devise Rail, Orthex, The Fassier-Duval Telescopic Intramedullary System, SLIM Nail, The GAP Nail, The Free Gliding SCFE Screw System, GIRO Growth Modulation System, PNP Tibia System, ApiFix Mid-C System and Mitchell Ponset specialized bracing products to various hospitals and medical facilities throughout the United States and various international markets. It markets 80 surgical and specialized bracing systems.

AI 分析 of OrthoPediatrics Corp (KIDS)

买入

OrthoPediatrics Corp (KIDS) is a good buy right now due to its current price of $21.95, which is below the analyst price target of $29 set by BTIG. The company has shown significant revenue growth, with Q2 revenue reaching $70.51 million, a 15.4% increase year-over-year, and a gross margin of 74%. However, the main risk is the negative earnings per share (EPS) of -0.30 reported in Q2, which reflects ongoing profitability challenges.

分析师评级(4)

上行空间 +4.40%
买入
4 买入
0 持有
0 卖出
当前: 22.03
最低
20.00
平均
23.00
最高
26.00

BTIG

2026-08-20

目标价

$29

买入

Truist

2026-08-05

目标价

$22

持有

Truist

2026-05-01

目标价

$17

持有

Canaccord

2026-04-24

目标价

$25

买入

Truist

2026-03-02

目标价

$20

持有

估值指标

OrthoPediatrics Corp(KIDS)当前预期市盈率为 0.00,5 年平均预期市盈率为 -39.53。

预期市盈率

严重高估
5 年均值 P/E
-39.53
当前P/E
0.00
高估
-20.20
低估
-58.87

预期 EV/EBITDA

合理
5 年均值 EV/EBITDA
92.40
当前EV/EBITDA
128.04
高估
181.87
低估
2.92

预期市销率

合理
5 年均值 P/S
4.36
当前P/S
1.91
高估
6.96
低估
1.76

Alphio AI 对 KIDS 的价格情景

情景价格取自当年最后一个月度预测区间。概率为固定的模型权重(25 / 50 / 25),不构成保证。

乐

乐观

乐观 · 25%KIDS

$28.44

情景价格

基

基准

基准 · 50%KIDS

$28.41

情景价格

悲

悲观

悲观 · 25%KIDS

$23.50

情景价格

持有 KIDS 的大户

B

Braidwell LP

+ 持有KIDS

+19.57%

3个月收益率

S

Soleus Capital Management, L.P.

+ 持有KIDS

-14.32%

3个月收益率

事件时间线

2026-04-30 (ET)

17:30:00

OrthoPediatrics Launches Traxio Complete Weight System

16:40:00

OrthoPediatrics Q1 Revenue $59.36M, Exceeds Expectations

2026-02-03 (ET)

07:10:00

OrthoPediatrics Partner iotaMotion Receives FDA Clearance for Expanded Pediatric Use

2026-01-12 (ET)

07:20:00

Generated Company Reports $236.1M Net Revenue for 2025

07:20:00

OrthoPediatrics Projects 2026 Revenue of $262M to $266M

资讯

KIDS 常见问题 —— 由 Alphio AI 解答

OrthoPediatrics Corp. is an orthopedic company, which is focused on advancing the field of pediatric orthopedics. The Company is engaged in designing, developing, and marketing anatomically appropriate implants and devices for children with orthopedic conditions, giving pediatric orthopedic surgeons and caregivers. The Company sells its specialized products, including PediLoc, PediPlates, Cannulated Screws, PediFlex nail, PediNail, PediLoc Tibia, ACL Reconstruction System, Locking Cannulated Blade, Locking Proximal Femur, Spica Tables, RESPONSE Spine, BandLoc, Devise Rail, Orthex, The Fassier-Duval Telescopic Intramedullary System, SLIM Nail, The GAP Nail, The Free Gliding SCFE Screw System, GIRO Growth Modulation System, PNP Tibia System, ApiFix Mid-C System and Mitchell Ponset specialized bracing products to various hospitals and medical facilities throughout the United States and various international markets. It markets 80 surgical and specialized bracing systems. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

OrthoPediatrics Corp (KIDS) is a good buy right now due to its current price of $21.95, which is below the analyst price target of $29 set by BTIG. The company has shown significant revenue growth, with Q2 revenue reaching $70.51 million, a 15.4% increase year-over-year, and a gross margin of 74%. However, the main risk is the negative earnings per share (EPS) of -0.30 reported in Q2, which reflects ongoing profitability challenges.

4 analysts cover KIDS: 4 rate it Buy, 0 Hold and 0 Sell. The average price target is 23.00.

暂无帖子

注册或登录后参与讨论

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

开始交易